Objective: a strong association has been observed between celiac disease, generally its silent clinical form, and autoimmune disorders. A potential correlation with inflammatory bowel disease has also been suggested. Anti-tissue transglutaminase antibodies have been detected in Crohn’s disease. We investigated the prevalence of celiac disease in patients with autoimmune diabetes and in Crohn’s disease patients and also evaluated the correlation between anti-transglutaminase antibody positivity and the clinical status of these diseases.

Methods: anti-tissue transglutaminase and anti-endomysium antibodies were assessed by enzyme-linked immunosorbent assay and indirect immunofluorescence, respectively. Upper digestive endoscopy and duodenal biopsy were indicated for cases with positive serology.

Results: anti-transglutaminase antibodies were detected in five diabetic patients (prevalence of 11.1%), only one serum sample was positive for IgG isotypes. Nine of thirty-three patients with Crohn’s disease had low positive levels for IgA anti-transglutaminase. Anti-endomysium antibodies were detected only in celiac patients. Celiac disease was confirmed in all diabetic patients submitted to duodenal biopsies who presented both anti-transglutaminase and anti-endomysium antibodies positivity. In Crohn’s disease, its clinical status and the diagnosis of celiac disease were not associated with positive anti-transglutaminase result.

Conclusions: the prevalence of celiac disease was high in diabetic patients. Anti-tissue transglutaminase antibodies were sensitive and specific markers of celiac disease in this diabetic group, while these antibodies were of limited value for celiac disease screening in patients with Crohn’s disease.

Key words: Anti-tissue transglutaminase. Celiac disease. Crohn’s disease. Diabetes mellitus.
cells. This enzyme plays an important role in apoptosis and has been reported to be actively involved in the wound healing process (12, 13).

Anti-tTG antibodies have been identified in inflammatory bowel disease, suggesting a low specificity of these antibodies for the diagnosis of celiac disease. This observation was attributed to tissue lesions or to the inflammatory activity presented in patients with inflammatory bowel disease (14, 15).

IgG antibodies against tTG have been detected in autoimmune diseases not associated with celiac disease (16, 17).

Based on the hypothesis that celiac disease is associated with autoimmune diabetes and Crohn’s disease or that the occurrence of anti-tTG antibodies, especially IgG, is triggered by an autoimmune condition, we assessed IgA and IgG anti-tTG antibodies using specific human tTG antigen. The focus this study was the diagnosis of celiac disease in patients with autoimmune diabetes and in a group of patients with Crohn’s disease. We also evaluated the correlation between anti-tTG positivity and the clinical status of these diseases in those patients whose celiac disease was not diagnosed.

PATIENTS AND METHODS

Patients

The study was approved by the Ethics Committee of our institution and informed consent was obtained from all patients.

Celiac disease was investigated in 45 consecutively selected patients with autoimmune diabetes (18). Twenty-four of the patients were female, the median age was 18 years (range: 14 to 26), and the median duration of diabetes was 8 years (range: 1 to 14).

Thirty-three patients with Crohn’s disease were diagnosed according to clinical, radiological, endoscopic and morphological criteria. Eighteen women and 15 men with a median age of 42 years (range: 18-72) and a disease duration of 9 years (range: 1-24) were studied. Inflammatory activity was assessed using the Harvey-Bradshaw simple clinical index (19) and by laboratorial tests (serum albumin) (20). Disease location and behavior were classified according to the Montreal classification for Crohn’s disease (21).

Serological tests

The patients were submitted to the investigation of anti-human tTG (IgA and IgG) and anti-endomysial (IgA) antibodies. All serum samples were tested in duplicate. IgA and IgG anti-human tTG antibodies were measured by enzyme-linked immunosorbent assay using a commercial kit (Quanta Lite™, Inova Diagnostics, Inc., San Diego, CA, USA) according to manufacturer instructions. Absorbance was read at 450 nm. Antibody titers > 20 arbitrary units (AU)/mL were defined as positive. IgA anti-endomysial antibodies were detected by indirect immunofluorescence using monkey esophagus as substrate (ImmuGlo™ kit, Immco Diagnostics, Buffalo, NY, USA) according to manufacturer instructions. A titer > 1:10 was considered to be positive.

Upper digestive endoscopy and histological analysis

Upper digestive endoscopy and duodenal biopsy were indicated for cases presenting positive serology. Excluded from this phase of the study were diabetic patients with autonomic neuropathy and patients regularly taking nonsteroidal anti-inflammatory drugs.

Biopsies were obtained from the distal duodenum, fixed in 10% formalin, processed for paraffin embedding, and stained with hematoxylin-eosin. All slides were examined under a light microscope at 400X magnification under the supervision of an experienced pathologist in the diagnosis of celiac disease.

The number of intraepithelial lymphocytes (IELs) and epithelial cell nuclei was counted in an uninterrupted sequence of superficial epithelium, for a total of 300 epithelial cells. The number of lymphocytes found, excluding those crossing the basement membrane, was expressed as the proportion per 100 epithelial cells. Infiltrative lesion (type 1 lesion) was defined as IELs density higher than 30 lymphocytes/100 epithelial cells.

The histological alterations observed in the duodenal mucosa that corresponding to those described for celiac disease were classified according to the criteria adopted by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and by the Working Group of the United European Gastroenterology Week (22, 23).

Statistical analysis

Data are expressed as mean or median and range. Quantitative variables were compared by the Mann-Whitney U test. Differences in the distribution of categorical data were compared using the chi-square test or Fisher’s exact test, when required. A p value < 0.05 was considered to be statistically significant.

RESULTS

All patients ingested gluten regularly.

Serological tests

Anti-tTG antibodies (IgA) were detected in four diabetic patients, with a median titer of 95.9 AU/mL (48.3 to 130). These cases also tested positive for anti-endomysial anti-
bodies, with a median titer of 1:40 (1:40 to 1:240). Only one serum sample was positive for IgG anti-tTG, with a titer of 85.5 AU/mL. This sample belonged to a diabetic patient who was IgA deficient (serum level < 7 mg/dL).

Nine of the 33 patients with Crohn’s disease were positive for IgA anti-tTG antibodies, with a mean titer of 25.54 ± 5.23 AU/mL (Fig. 1). Anti-endomysial antibodies were not detected in any of these patients. Two serum samples presented homogeneous fluorescence of the whole myofibril, suggesting the presence of smooth muscle antibodies at low levels.

**Upper digestive endoscopy and histological analysis**

Fourteen subjects were selected for upper digestive endoscopy. Three of the Crohn’s disease patients refused to undergo the procedure and were excluded from the study.

All diabetic patients who were submitted to endoscopy presented histological alterations compatible with those described for celiac disease and received a gluten-free diet. The mean density of IELs in the duodenal biopsies of these patients was 50.8 ± 18.14 lymphocytes/100 epithelial cells.

The duodenal biopsies of Crohn’s disease patients showed a preserved villous architecture. The mean density of IELs was 12.17 ± 6.59 lymphocytes/100 epithelial cells and this was significantly different from that of celiac diabetic patients (p = 0.04).

No association was observed between anti-tTG positivity and clinical status of the Crohn disease (Tables I and II).

**DISCUSSION**

Transglutaminase is an enzyme widely found in human organs, which is involved in various physiological processes such as extracellular matrix formation, apoptosis and intestinal mucosal healing (13,24).

Type 1 diabetes mellitus is an organ-specific autoimmune disease resulting from the destruction of insulin-producing pancreatic beta cells. Glutamic acid decarboxylase (GADA) is a beta-cell autoantigen. T cells have been shown to play a critical role in the destruction of beta cells, with the content of apoptotic bodies coming in contact with the immune system, which leads to an autoimmune response (25). We used autoantibodies to anti-GADA as a marker of autoimmunity in the type 1 diabetic patients studied here. No association was observed between the presence of the GADA and anti-tTG positivity (data not shown).

We found a significant increase in anti-tTG titers in diabetic patients with diagnosis of celiac disease. The absence of anti-tTG antibodies in autoimmune diabetes not associated with celiac disease suggests that its positivity in celiac diabetic patients is a fact that may not be related to autoimmunity alone.

In celiac disease, the sensitivity of IgG anti-tTG antibodies is close to 100% in IgA-deficient patients (26). In the present study, the only serum sample that tested positive for these antibodies belonged to a celiac patient with IgA deficiency.
We observed low positive levels of anti-tTG (IgA) in patients with Crohn’s disease, whose duodenal biopsies showed a preserved villous architecture. Several studies have shown that the prevalence and serum levels of anti-tTG antibodies depend on the degree of histological damage in celiac disease (27,28). It is possible that the presence of severe villous atrophy had been responsible for the higher serum anti-tTG titers observed in diabetic celiac patients when compared to Crohn’s disease patients.

Large numbers of villous IELs was described during an episode of active Crohn’s enteritis (29). However, Wright et al. (30) found a similar IEL density in the duodenum of Crohn’s disease patients with normal radiographic and endoscopic findings in agreement with our results.

Di Tola et al. (15) reported a relationship between anti-tTG positivity and Crohn’s disease activity, although the degree of intestinal damage had not been described. No such relationship was demonstrated in the present study. This discrepancy might be due to differences in the criteria used to define inflammatory activity in Crohn’s disease or in the histopathological features.

Complications of diabetes mellitus such as autonomic neuropathy classically occur in patients with long-term disease. The knowledge that the presence of this motor disorder may favor the occurrence of an inflammatory process in the intestinal mucosa (31) led us to study patients with recent-onset diabetes. The Crohn’s disease patients in our study were older than the diabetic ones. However, this demographic characteristic did not interfere with the present results since anti-tTG antibodies have not been reported to be related to age in adolescent and adult patients (32).

Farrace et al. (14) demonstrated that tTG is released by fibroblasts into the extracellular matrix in the intestine of celiac patients. In the present study, anti-endomysial antibodies were only detected in patients with celiac disease. However, a homogeneous intracellular fluorescence pattern was observed in two patients with Crohn’s disease.

Antibodies reacting with components of the cytoskeleton have been described in patients with inflammatory bowel disease (33) and celiac disease. Pedreira et al. (34) found an association between the presence of these antibodies and the severity of gut injury in celiac patients. The identification of cytoplasmic actin as an abundant glutaminyl substrate for tTG in leukemia –derived human cell lines undergoing apoptosis (35) suggests that intracellular transglutaminase might be the antigen related to this fluorescence pattern. Thus, the presence of anti-smooth muscle antibodies and anti-endomysium antibodies might indicate a distinct antigenic expression patterns for tTG. Villous atrophy might be necessary to trigger an increase of anti-tTG antibody titers and the appearance of anti-endomysin in these diseases. Further studies are still needed to investigate the relationship between anti-tTG antibodies and duodenal villous atrophy in Crohn’s disease in order to determine whether this pattern of tissue injury is responsible for the elevated titers of these antibodies.

ACKNOWLEDGMENTS

We thank Dr. Sérgio Atala Dib and Dr. Mônica Andrade Lima Gabbay for assistance in our study.

REFERENCES